Cargando…
Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov
BACKGROUND: Patient‐reported adverse events (AEs) may be a useful adjunct to clinician‐assessed AEs for assessing tolerability in early phase, dose‐finding oncology trials (DFOTs). We reviewed DFOTs on ClinicalTrials.gov to describe trends in patient‐reported outcome (PRO) use. METHODS: DFOTs commen...
Autores principales: | Lai‐Kwon, Julia, Yin, Zhulin, Minchom, Anna, Yap, Christina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607259/ https://www.ncbi.nlm.nih.gov/pubmed/34676991 http://dx.doi.org/10.1002/cam4.4307 |
Ejemplares similares
-
Registration of phase 3 crossover trials on ClinicalTrials.gov
por: Zeng, Lijuan, et al.
Publicado: (2020) -
Characteristics of Phase IV Clinical Trials in Oncology: An Analysis Using the ClinicalTrials.gov Registry Data
por: Henry, Brandon Michael, et al.
Publicado: (2023) -
Characteristics of Depression Clinical Trials Registered on ClinicalTrials.gov
por: Liang, Juan, et al.
Publicado: (2022) -
Some data quality issues at ClinicalTrials.gov
por: Chaturvedi, Neha, et al.
Publicado: (2019) -
Obstacles to the reuse of study metadata in ClinicalTrials.gov
por: Miron, Laura, et al.
Publicado: (2020)